Gerresheimer Revises 2025 Financial Guidance

Gerresheimer AG has adjusted its financial guidance for 2025, citing subdued demand in the cosmetics sector and a decline in the need for containment solutions for oral liquid medications. The company's second-quarter organic revenue growth is projected to be in the low single digits, with an adjusted EBITDA margin around 19%. This revision marks a decrease from the previously anticipated growth, reflecting lower-than-expected performance in the first half of 2025.

Consequently, Gerresheimer has revised its full-year financial outlook, now expecting organic revenue growth of 1-2% and an adjusted EBITDA margin of 20%, down from the previously estimated 3-5% growth and 22% margin. The company aims to sustain long-term growth, focusing on biologics and containment solutions.

Additionally, the Executive Board has proposed a reduced dividend of 4% of share capital for the 2024 financial year to maintain financial flexibility. This proposal will be discussed at the Annual General Meeting in June 2025.